Table 4.
Multivariate survival analysis of BCFI
| Characteristic | BCFI |
|
|---|---|---|
| p-value | Hazard ratio (95% CI) | |
| Age (yr) | ||
| < 60 | 0.156 | 1 |
| ≥ 60 | 1.58 (0.84-2.96) | |
| Tumor size (cm) | ||
| < 2 | 0.006 | 1 |
| ≥ 2 | 2.85 (1.36-6.00) | |
| Axillary lymph node status | ||
| Negative | 0.230 | 1 |
| Positive | 1.45 (0.79-2.66) | |
| Histological grade | ||
| I-II | 0.072 | 1 |
| III | 1.83 (0.95-3.51) | |
| NA | 3.01 (0.99-9.09) | |
| Molecular subtype | ||
| Luminal A | 0.857 | |
| Luminal B-HER2– | 1.59 (0.46-5.49) | |
| Luminal B-HER2+ | 2.21 (0.55-8.91) | |
| HER2 positive | 1.83 (0.42-7.92) | |
| Triple-negative | 0.62 (0.33-1.17) | |
| Surgery time interval (day) | ||
| < 4 | 0.211 | 1 |
| ≥ 4 | 0.67 (0.36-1.25) | |
| CNB-LPBC status | ||
| nLPBC | 0.969 | 1 |
| LPBC | 0.00 (0.00-8.85279) | |
| LPBC change pattern | ||
| nLPBC→nLPBC, LPBC→LPBC, or LPBC→nLPBC | 0.035 | 1 |
| nLPBC→LPBC | 2.19 (1.06-4.53) | |
Pathological data is based on surgery removed sample if not specified. BCFI, breast cancer-free interval; CI, confidence interval; NA, not available; HER2, human epidermal growth factor receptor 2; CNB, core needle biopsy; LPBC, lymphocytepredominant breast cancer; nLPBC, non-lymphocyte-predominant breast cancer.